Attana features in Pharma Publications with AVA™ as a leading-edge solution for improved SARS-CoV-2 testing and immunity profiling
Recently, an article about Attana’s first non-clinical in vitro diagnostic (IVD) device, Attana Virus Analytics – AVA™, was published in IBI (International Biopharmaceutical Industry). The article explains how AVA could help provide invaluable insights when assessing patient immunity for SARS-CoV-2.
A brief summary of the article:
The Challenge of Assessing SARS-CoV-2 Immunity
One of the main challenges with SARS-CoV-2 is assessing patient immunity. Conventional testing methods focuse on the binary presence of virus-specific antibodies (e.g. IgA, IgM and IgG). However, SARS-CoV-2 immunity assessments requires a more nuanced analysis of the immune response, since a significant number of SARS-CoV-2 positive individuals have not developed any discernable antibody counts post-infection.
A Solution for Improved SARS-CoV-2 Immunity Assessing
Attana Virus Analytics – AVA™ is a generic IVD device for non-clinical laboratory use, consisting of Attana’s proprietary third-generation biosensor, various assays, and reagents. This technology enables AVA™ to take a broader approach when assessing immunity compared with the most prevalent virus diagnostics tools that are traditional based on ELSIA assays. By comparing an individual’s immune responses in a series of tests, a full patient immunity profile can be established and manifested. The AVA™ platform could therefore provide invaluable insights on an individual patient level, as well as the most suitable vaccination programmes based on the population’s immunity.
Nest steps for AVA™ platform
Although Attana recently entered the IVD market, our biosensor instruments have been used by Big Pharma, biotech companies, and academia for over 18 years and been highlighted in over 130 peer-reviewed publications. Attana have recently initiated a regulatory approval process for the AVA™ platform and will continue to engage in cross-disciplinary development of a point-of-care IVD device with AI-enabled automated analytic capabilities.
Read the full article here.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
+ 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact [email protected]
Dignitana-backed insurance legislation clears Texas House, progresses to Senate
Dignitana AB,world leader in scalp cooling innovation, announces today that HB1588, a Bill mandating insurance plan coverage for scalp cooling in Texas, was passed in the Texas House of Representatives on Friday. The Bill was introduced by Rep. Jeff Leach and 4 other legislators and now moves...
AdderaCares förvärv av Linds Ortopediska godkänns av Region Stockholm
AdderaCare AB offentliggjorde den 24 mars intentionen att förvärva Linds Ortopediska AB (Linds) givet att Region Stockholm godkänner förändringen mot bakgrund av Linds ramavtal om leverans av ortopedtekniska lösningar till regionen. Region Stockholm har i dag meddelat a...
LIDDS Annual Report 2020
LIDDS AB is required to disclose this information pursuant to Nasdaq First North Growth Market – Rulebook. The information was submitted for publication, through the agency of the aforementioned contact person, on April 16, 2021 at 15:00 CET. LIDDS AB (publ) is a Swedish-based pharmaceutical compan...
Bulletin from the Annual General Meeting in Implantica AG
The general meeting adopted the annual report 2020 consisting of the statutory financial statements and the consolidated financial statements of Implantica AG for the financial year 2020 and resolved, in accordance with the board of directors’ proposal, to carry forward the net loss for the financia...